Hydrocortisone succinate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Hydrocortisone succinate
Accession Number
DB14545
Type
Small Molecule
Groups
Approved
Description
Not Available
Structure
Thumb
Synonyms
  • Cortisol 21-(hydrogen succinate)
  • Cortisol succinate
  • Hydrocortisone hemisuccinate anhydrous
  • Hydrocortisone hydrogen succinate
  • Hydroxycortisone succinate
Product Ingredients
IngredientUNIICASInChI Key
Hydrocortisone sodium succinate50LQB69S1Z125-04-2HHZQLQREDATOBM-CODXZCKSSA-M
Hydrocortisone succinate monohydrateLIU00Z1Z8483784-20-7AFLWPAGYTPJSEY-CODXZCKSSA-N
Active Moieties
NameKindUNIICASInChI Key
HydrocortisoneunknownWI4X0X7BPJ50-23-7JYGXADMDTFJGBT-VWUMJDOOSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Solu-CortefInjection, powder, for solution100 mg/2mLIntramuscular; IntravenousPharmacia & Upjohn Inc1955-04-27Not applicableUs
Solu-cortefInjection, powder, for solution250 mg/2mLIntramuscular; IntravascularPharmacia & Upjohn Inc1980-04-272014-10-01Us
Solu-cortefInjection, powder, for solution100 mg/2mLIntramuscular; IntravascularCardinal Health1955-04-272015-02-28Us
Solu-cortefInjection, powder, for solution100 mg/2mLIntramuscular; IntravascularPharmacia & Upjohn Inc1980-04-272015-02-01Us
Solu-CortefInjection, powder, for solution1000 mg/8mLIntramuscular; IntravenousPharmacia & Upjohn Inc1955-04-27Not applicableUs
Solu-CortefInjection, powder, for solution100 mg/2mLIntramuscular; IntravenousPharmacia & Upjohn Inc1955-04-27Not applicableUs
Solu-CortefInjection, powder, for solution100 mg/2mLIntramuscular; IntravenousPhysicians Total Care, Inc.1955-04-272013-06-01Us
Solu-CortefInjection, powder, for solution100 mg/2mLIntramuscular; IntravenousCardinal Health1955-04-27Not applicableUs
Solu-CortefInjection, powder, for solution500 mg/4mLIntramuscular; IntravenousPharmacia & Upjohn Inc1955-04-27Not applicableUs
Solu-cortefInjection, powder, for solution1000 mg/8mLIntramuscular; IntravascularPharmacia & Upjohn Inc1980-04-272014-05-01Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
A-hydrocortInjection, powder, lyophilized, for solution100 mg/2mLIntramuscular; IntravenousHospira, Inc.2006-12-142010-07-01Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
IHV1VP592V
CAS number
2203-97-6
Weight
Average: 462.539
Monoisotopic: 462.225368055
Chemical Formula
C25H34O8
InChI Key
VWQWXZAWFPZJDA-CGVGKPPMSA-N
InChI
InChI=1S/C25H34O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1
IUPAC Name
4-{2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be increased when combined with Hydrocortisone succinate.
(S)-WarfarinThe metabolism of (S)-Warfarin can be increased when combined with Hydrocortisone succinate.
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Hydrocortisone succinate.
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Hydrocortisone succinate.
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Hydrocortisone succinate.
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Hydrocortisone succinate.
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Hydrocortisone succinate.
1alpha,24S-Dihydroxyvitamin D2The therapeutic efficacy of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when used in combination with Hydrocortisone succinate.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Hydrocortisone succinate.
2,4-thiazolidinedioneThe risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with 2,4-thiazolidinedione.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D01442
ChemSpider
15760
BindingDB
50016931
ChEBI
31677
ChEMBL
CHEMBL977
Wikipedia
Hydrocortisone_hemisuccinate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic ScienceSleep Restriction1
1CompletedNot AvailableInfection NOS1
1RecruitingBasic ScienceSleep Restriction1
1RecruitingTreatmentLymphoblastic Leukemia, Acute, Childhood / Lymphoma, Lymphoblastic / Peripheral T-Cell Lymphoma (PTCL)1
1TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, Lymphoblastic, Acute, T Cell / Lymphoblastic Leukemia, Acute, Childhood1
1, 2RecruitingTreatmentAddison's Disease / Adrenal Hyperplasia Congenital1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma1
2CompletedTreatmentAcute Respiratory Distress Syndrome (ARDS) / Multiple Organ Failure1
2CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentLeukemias1
2CompletedTreatmentPaediatric Sepsis / Pediatric Sepsis / Sepsis1
2RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / B Acute Lymphoblastic Leukemia / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)1
2RecruitingTreatmentAdrenal Hyperplasia, Congenital1
2RecruitingTreatmentApomorphine-induced Skin Reactions / Parkinson's Disease (PD)1
2Unknown StatusTreatmentLeukemias1
2, 3Active Not RecruitingTreatmentAsphyxia / Hypoxic-Ischaemic Encephalopathy1
2, 3CompletedTreatmentAddison's Disease1
2, 3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Ann Arbor Stage II Adult Lymphoblastic Lymphoma / Ann Arbor Stage II Childhood Lymphoblastic Lymphoma / Ann Arbor Stage III Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Childhood Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult Lymphoblastic Lymphoma / Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult Lymphoblastic Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3CompletedSupportive CareCardiac Toxicity / Leukemias / Malignant Lymphomas1
3CompletedTreatmentLeukemias / Malignant Lymphomas1
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
3CompletedTreatmentProstate Cancer1
3CompletedTreatmentShock, Septic1
3RecruitingSupportive CareSepsis1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentShock, Septic1
4CompletedTreatmentShock1
4CompletedTreatmentShock, Septic2
4RecruitingTreatmentUlcerative Colitis1
Not AvailableCompletedTreatmentAdrenal Hyperplasia, Congenital1
Not AvailableRecruitingTreatmentIntussusception1
Not AvailableSuspendedNot AvailableSome Studies Shows That the Steroid Can Reduce the Injury of the I/R of the Liver1
Not AvailableUnknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous100 mg/2mL
Injection, powder, for solutionIntramuscular; Intravascular100 mg/2mL
Injection, powder, for solutionIntramuscular; Intravascular1000 mg/8mL
Injection, powder, for solutionIntramuscular; Intravascular250 mg/2mL
Injection, powder, for solutionIntramuscular; Intravascular500 mg/4mL
Injection, powder, for solutionIntramuscular; Intravenous100 mg/2mL
Injection, powder, for solutionIntramuscular; Intravenous1000 mg/8mL
Injection, powder, for solutionIntramuscular; Intravenous250 mg/2mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/4mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0653 mg/mLALOGPS
logP2.17ALOGPS
logP1.54ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)3.66ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area138.2 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity117.44 m3·mol-1ChemAxon
Polarizability48.68 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Joellenbeck L, Qian Z, Zarba A, Groopman JD: Urinary 6 beta-hydroxycortisol/cortisol ratios measured by high-performance liquid chromatography for use as a biomarker for the human cytochrome P-450 3A4. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec;1(7):567-72. [PubMed:1302569]
  2. Litt J. (2016). Litt's Drug eruption & reaction manual (22nd ed.). CRC Press LLc.
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Bauersachs J, Christ M, Ertl G, Michaelis UR, Fisslthaler B, Busse R, Fleming I: Cytochrome P450 2C expression and EDHF-mediated relaxation in porcine coronary arteries is increased by cortisol. Cardiovasc Res. 2002 Jun;54(3):669-75. [PubMed:12031713]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Freel EM, Shakerdi LA, Friel EC, Wallace AM, Davies E, Fraser R, Connell JM: Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33. doi: 10.1210/jc.2004-0379. [PubMed:15356073]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name
CYP11B2
Uniprot ID
P19099
Uniprot Name
Cytochrome P450 11B2, mitochondrial
Molecular Weight
57559.62 Da
References
  1. Freel EM, Shakerdi LA, Friel EC, Wallace AM, Davies E, Fraser R, Connell JM: Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33. doi: 10.1210/jc.2004-0379. [PubMed:15356073]

Drug created on July 12, 2018 15:25 / Updated on November 02, 2019 04:43